Q-omics provides the consensus-scored RUBCN profile across patient tissues and cancer cell-line models. RUBCN expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RUBCN is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, RUBCN RNA expression shows 20,435 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, HNSC, and ACC as cancer lineages where RUBCN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RUBCN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RUBCN survival associations across molecular data types. RUBCN RNA expression shows survival associations in the most cancer types (17), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RUBCN RNA expression–survival associations across cancer types. High RUBCN expression shows unfavorable associations in LIHC, UCEC, MESO and LUSC, but favorable associations in KIRC and ESCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RUBCN RNA expression.
This table summarizes RUBCN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RUBCN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RUBCN shows higher tumor expression in HNSC, LIHC, THCA, BRCA, CHOL and KIRC. The HNSC box plot shows higher RUBCN RNA expression in tumor versus normal tissue (log2 FC = +0.796, t-test p < 0.001).
This table shows molecular features associated with RUBCN in patient tissues and cancer cell lines. In patient samples, RUBCN shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RUBCN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
